JP2013523696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523696A5 JP2013523696A5 JP2013501865A JP2013501865A JP2013523696A5 JP 2013523696 A5 JP2013523696 A5 JP 2013523696A5 JP 2013501865 A JP2013501865 A JP 2013501865A JP 2013501865 A JP2013501865 A JP 2013501865A JP 2013523696 A5 JP2013523696 A5 JP 2013523696A5
- Authority
- JP
- Japan
- Prior art keywords
- mirna
- antagonist
- expression
- antisense
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims 15
- 230000014509 gene expression Effects 0.000 claims 8
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 208000007474 aortic aneurysm Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims 4
- -1 COL1A3 Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108020004491 Antisense DNA Proteins 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims 2
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims 2
- 102100033167 Elastin Human genes 0.000 claims 2
- 108010014258 Elastin Proteins 0.000 claims 2
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000003816 antisense DNA Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 108060002895 fibrillin Proteins 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 108700000163 miRNA-29b Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 206010060874 Aortic rupture Diseases 0.000 claims 1
- 101150108568 ELN gene Proteins 0.000 claims 1
- 102000016942 Elastin Human genes 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 101150062966 FBN1 gene Proteins 0.000 claims 1
- 102100031509 Fibrillin-1 Human genes 0.000 claims 1
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 229920002549 elastin Polymers 0.000 claims 1
- 102000013370 fibrillin Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10003675.5 | 2010-04-01 | ||
| EP10003675A EP2371370A1 (en) | 2010-04-01 | 2010-04-01 | Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization |
| PCT/EP2011/055122 WO2011121120A1 (en) | 2010-04-01 | 2011-04-01 | ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016060073A Division JP2016193888A (ja) | 2010-04-01 | 2016-03-24 | ｍｉＲＮＡ−２９発現のアンタゴニスト、並びに大動脈瘤の予防及び治療におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523696A JP2013523696A (ja) | 2013-06-17 |
| JP2013523696A5 true JP2013523696A5 (enExample) | 2014-05-15 |
| JP6224455B2 JP6224455B2 (ja) | 2017-11-01 |
Family
ID=42269707
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501865A Active JP6224455B2 (ja) | 2010-04-01 | 2011-04-01 | ｍｉＲＮＡ−２９発現のアンタゴニスト、並びに大動脈瘤の予防及び治療におけるその使用 |
| JP2016060073A Pending JP2016193888A (ja) | 2010-04-01 | 2016-03-24 | ｍｉＲＮＡ−２９発現のアンタゴニスト、並びに大動脈瘤の予防及び治療におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016060073A Pending JP2016193888A (ja) | 2010-04-01 | 2016-03-24 | ｍｉＲＮＡ−２９発現のアンタゴニスト、並びに大動脈瘤の予防及び治療におけるその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9062307B2 (enExample) |
| EP (2) | EP2371370A1 (enExample) |
| JP (2) | JP6224455B2 (enExample) |
| CN (1) | CN102939090A (enExample) |
| AU (1) | AU2011234453B2 (enExample) |
| CA (1) | CA2795164C (enExample) |
| ES (1) | ES2690198T3 (enExample) |
| RU (1) | RU2012146518A (enExample) |
| WO (1) | WO2011121120A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
| US8618073B2 (en) | 2010-07-22 | 2013-12-31 | The University Of North Carolina At Chapel Hill | Use of miR-29 for cell protection |
| JP2015518475A (ja) * | 2012-04-10 | 2015-07-02 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） | 非アルコール性脂肪性肝炎の治療方法 |
| EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY |
| US9828603B2 (en) | 2012-08-13 | 2017-11-28 | Cedars Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| RU2712511C2 (ru) * | 2014-09-08 | 2020-01-29 | Мираген Терапеутикс, Инк. | Миметики mir-29 и пути их применения |
| US11357799B2 (en) | 2014-10-03 | 2022-06-14 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| EP3247716A4 (en) | 2015-01-20 | 2018-10-17 | Miragen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
| EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| WO2017214949A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种抑制 miRNA-29a 表达的慢病毒载体的构建及其应用 |
| WO2017219170A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用 |
| WO2017219169A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 一种抑制 miRNA-29a 和 miR-185 表达的慢病毒载体及其应用 |
| EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS |
| US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| CN109762883B (zh) * | 2019-01-31 | 2020-01-21 | 温州医科大学 | 血浆/血清外泌体hsa-miRNA-29-3p作为青光眼诊断标志物中的应用 |
| CN110511930B (zh) * | 2019-06-11 | 2023-01-10 | 河北医科大学 | Sal-miR-58及其在抑制血管炎性反应和动脉瘤形成中的用途 |
| CN117979975A (zh) * | 2021-05-07 | 2024-05-03 | 加利福尼亚大学董事会 | 用于预防和治疗动脉瘤、高血压、ards和其他与内皮功能障碍相关联的疾病的mirna抑制剂 |
| US20250304956A1 (en) * | 2021-08-06 | 2025-10-02 | Leadermed Champion Limited | miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF |
| CN114432453B (zh) * | 2022-02-25 | 2022-10-14 | 上海大学 | 敲低或抑制clec4d的试剂在制备心肌缺血再灌注损伤药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008042231A2 (en) | 2006-09-29 | 2008-04-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| ES2621161T3 (es) | 2007-07-31 | 2017-07-03 | The Board Of Regents Of The University Of Texas System | Familia de micro-ARN que modula la fibrosis y usos de la misma |
| CL2008003699A1 (es) * | 2007-12-13 | 2009-10-09 | Takeda Pharmaceuticals Co | Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas. |
| CA2716343A1 (en) * | 2008-02-21 | 2009-08-27 | The Board Of Regents Of The University Of Texas System | Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof |
-
2010
- 2010-04-01 EP EP10003675A patent/EP2371370A1/en not_active Withdrawn
-
2011
- 2011-04-01 JP JP2013501865A patent/JP6224455B2/ja active Active
- 2011-04-01 AU AU2011234453A patent/AU2011234453B2/en active Active
- 2011-04-01 WO PCT/EP2011/055122 patent/WO2011121120A1/en not_active Ceased
- 2011-04-01 EP EP11711597.2A patent/EP2552454B1/en active Active
- 2011-04-01 RU RU2012146518/15A patent/RU2012146518A/ru not_active Application Discontinuation
- 2011-04-01 CN CN2011800172888A patent/CN102939090A/zh active Pending
- 2011-04-01 CA CA2795164A patent/CA2795164C/en active Active
- 2011-04-01 US US13/637,924 patent/US9062307B2/en active Active
- 2011-04-01 ES ES11711597.2T patent/ES2690198T3/es active Active
-
2016
- 2016-03-24 JP JP2016060073A patent/JP2016193888A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523696A5 (enExample) | ||
| RU2012146518A (ru) | Антагонисты экспрессии мкрнк-29 и их применение в профилактике и лечении аневризмы аорты | |
| Li et al. | A novel circular RNA, hsa_circ_0046701, promotes carcinogenesis by increasing the expression of miR-142-3p target ITGB8 in glioma | |
| Mishra et al. | MicroRNA reexpression as differentiation therapy in cancer | |
| Van Rooij et al. | MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles | |
| Condorelli et al. | microRNAs in cardiovascular diseases: current knowledge and the road ahead | |
| DK2684955T3 (en) | Method to promote angionesis, vascularization or vascular repair or to inhibit tumor angionesis | |
| CA3134991A1 (en) | Pharmaceutical composition for treating cancer comprising microrna as active ingredient | |
| JP2007528736A5 (enExample) | ||
| Kalozoumi et al. | MicroRNAs in heart failure: Small molecules with major impact | |
| EP3665281A1 (en) | CONDITIONAL-siRNAS AND USES THEREOF IN TREATING CARDIAC HYPERTROPHY | |
| Kartha et al. | MicroRNAs in cardiovascular diseases: biology and potential clinical applications | |
| WO2019033083A1 (en) | CONDITIONAL RNAIDS AND THEIR USES IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA | |
| Fernandes-Silva et al. | Physical exercise and microRNAs: new frontiers in heart failure | |
| Kotsinas et al. | MicroRNAs determining inflammation as novel biomarkers and potential therapeutic targets | |
| Papageorgiou et al. | The role of microRNAs in the initiation and progression of stable atheromatous plaque | |
| JP2019518439A (ja) | 心臓リモデリングの治療及び診断のためのｌｎｃＲＮＡ Ｍｅｇ３ | |
| US12421552B2 (en) | MicroRNA-134 biomarker | |
| Dorn | MicroRNAs: redefining mechanisms in cardiac disease | |
| CA3226550A1 (en) | Mirna combination for the prevention and treatment of cancer | |
| Hassan et al. | Molecular mechanisms of cardiovascular benefits of exercise: Running for cover from heart disease | |
| EP4431117A1 (en) | Composition for diagnosis, prevention, or treatment of vascular smooth muscle cell proliferative disease, using mirna inhibitor | |
| Ding et al. | Role of MicroRNAs in cardiac hypertrophy and postinfarction remodeling | |
| Ranjan et al. | Circular RNAs in Organ Fibrosis | |
| Yu et al. | MicroRNA as predictive and informative diagnostic tools and promising drug targets to monitor chronic cardiac disorders and to manage the patients and persons-at-risks |